← All Oncology Institute, INC filings

Oncology Institute, INC 8-K filings

NASDAQ
TOI
Oncology Institute, INC
8-K: The Oncology Institute Faces Nasdaq Delisting Threat After Share Price Falls Below $1
The Oncology Institute has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing its listing at risk.
NASDAQ
TOI
Oncology Institute, INC
8-K: The Oncology Institute Holds 2024 Annual Meeting, Elects Directors and Approves Key Proposals
The Oncology Institute held its 2024 Annual Meeting, electing nine directors and approving the ratification of BDO USA, LLP as its independent auditor and the potential issuance of shares related to its financing agreement.
NASDAQ
TOI
Oncology Institute, INC
8-K: The Oncology Institute Reports Strong Revenue Growth but Declining Gross Profit in Q1 2024
The Oncology Institute (TOI) announced a 24.2% increase in revenue for the first quarter of 2024, alongside a decrease in gross profit and an adjusted EBITDA loss.
NASDAQ
TOI
Oncology Institute, INC
8-K: The Oncology Institute Reports 2023 Financial Results and Provides 2024 Guidance
The Oncology Institute (TOI) released its 2023 financial results and provided guidance for 2024, highlighting growth in revenue and value-based care.
NASDAQ
TOI
Oncology Institute, INC
8-K: The Oncology Institute Reports 20.1% Revenue Increase in Q4 2023, But Net Loss Widens
The Oncology Institute (TOI) announced a 20.1% increase in revenue for the fourth quarter of 2023, alongside a widened net loss and provided financial guidance for 2024.